Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Mirai Bio
Deal Size : Undisclosed
Deal Type : Partnership
Mirai Bio Partners with Thermo Fisher to Accelerate Genetic Medicines Development
Details : Through the collaboration, Thermo Fisher will be paired with Mirai's innovative technology platform for optimizing the design, delivery and development of novel nucleic acid therapeutics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 20, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Mirai Bio
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Deuterated Tryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Cybin
Deal Size : Undisclosed
Deal Type : Agreement
Cybin Taps Thermo Fisher to Manufacture CYB003 for Major Depression
Details : Thermo Fisher Scientific will providing Phase 3 capsule clinical supply and will support future commercial manufacturing efforts for CYB003 (deuterated tryptamine).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 15, 2025
Lead Product(s) : Deuterated Tryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Cybin
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Lyndra Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lyndra, Thermo Fisher Partner on Long-Acting Oral Therapy Development
Details : The collaboration aims to advance the Lynra late-stage product LYN-005 (risperidone), which is being evaluated for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 15, 2025
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Lyndra Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves NGS Diagnostic for Grade 2 IDH-Mutant Glioma Therapy
Details : Voranigo (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor IDH1/2 enzymes. It is approved by FDA for the treatment of IDH-mutant diffuse glioma in 12 year and above patients.
Product Name : Voranigo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 18, 2024
Galapagos Partners with Thermo Fisher To Expand CAR-T Manufacturing Network in the U.S.
Details : Thermo Fisher will provide GMP manufacturing, BioServices, and Specialty Logistics for Galapagos’ CAR-T hemato-oncology clinical program, GLPG-5101, developed for Non-Hodgkin’s lymphoma treatment.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 01, 2024
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Collaboration
Bayer and Thermo Fisher Collaborate To Enhance Access To Cancer Medicines
Details : The collaboration aims to develop sequencing-based companion diagnostics to identify patients who may benefit from Bayer’s precision cancer therapies, including Nubeqa for prostate cancer.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Undisclosed
March 20, 2024
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Tulisokibart
Therapeutic Area : Immunology
Study Phase : Phase III
Recipient : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 25, 2023
Lead Product(s) : Tulisokibart
Therapeutic Area : Immunology
Highest Development Status : Phase III
Recipient : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eblasakimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : ASLAN Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : ASLAN004 (eblasakimab) is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile for the treatment of moderate-to-severe atopic dermatitis (AD).
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 01, 2023
Lead Product(s) : Eblasakimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : ASLAN Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Elasomeran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration
Details : As part of this expanded agreement, Thermo Fisher will now provide dedicated capacity for a range of aseptic fill-finish services including lyophilized and liquid filling for Spikevax. In addition, the company will provide inspection, labeling and final ...
Product Name : Spikevax
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
February 23, 2022
Lead Product(s) : Elasomeran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration